Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib + trastuzumab neoadjuvant therapy for HER2-positive breast cancer
ChiCTR1900022293Phase 2Recruiting
- Sponsor
- Southwest Hospital of Army Medical University
- Start
- Jul 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pyrotinib, trastuzumab, epirubicin and cyclophosphamide in breast cancer, sponsored by Southwest Hospital of Army Medical University. Primary endpoints: Objective response rate, Pathologic complete response and 2 more. Started Jul 2020; status: recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR1900022293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022293.